APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035

Apollo HOSPITALS

12th August 2025

The Secretary,
Bombay Stock Exchange Ltd (BSE)
Phiroze Jheejheebhoy Towers,
Dalal Street,
Mumbai – 400 001.
Scrip Code – 508869
ISIN INE437A01024

The Secretary,
National Stock Exchange,
Exchange Plaza, 5th Floor
Plot No.C/1, 'G' Block
Bandra – Kurla Complex
Bandra (E)
Mumbai – 400 051.
Scrip Code–
APOLLOHOSP
ISIN INE437A01024

Dear Sir,

Subject: Disclosure under Regulation 30 the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Investor Presentation on the Financial Results of the Company for three months ended June 30, 2025.

The presentation to be made to the Investors is enclosed and the same is also being uploaded on the Company's website www.apollohospitals.com.

Kindly note of the same.

Thanking You,

Yours faithfully,
For APOLLO HOSPITALS ENTERPRISE LIMITED

SANKARANARA YANAN MUTHU KRISHNAN

Digitally signed by SANKARANARAYANAN MUTHU KRISHNAN
Date: 2025.08.12 19:40:27 +05'30'

S.M. KRISHNAN
Sr. VICE PRESIDENT – FINANCE
AND COMPANY SECRETARY

Apollo Hospitals Enterprise Limited

Earnings Update Q1 FY26

Disclaimer

The information contained in this presentation is provided by Apollo Hospitals Enterprise Limited (the “Company”) to you solely for your reference. This document is being given solely for your information and for your use and may not be retained by you and neither this presentation nor any part thereof may be (i) used or relied upon by any other party or for any other purpose; (ii) copied, photocopied, duplicated or otherwise reproduced in any form or by any means; or (iii) redistributed, passed on or otherwise disseminated, to any other person without the prior written consent of the Company. Although care has been taken to ensure that the information in this presentation is accurate, and that the opinions expressed are fair and reasonable, the information is subject to change without notice, its accuracy is not guaranteed and has not been independently verified. No representation, warranty, guarantee or undertaking (express or implied) is made as to, and no reliance should be placed on, the accuracy, completeness or correctness of any information, including any projections, estimates, targets and opinions, contained herein, and accordingly, none of the Company, its advisors, representatives or any of its directors assumes any responsibility or liability for, the accuracy or completeness of, or any errors or omissions in, any information or opinions contained herein. None of the Company, its advisors, representatives and its directors, officers, employees or affiliates nor any other person accepts any responsibility or liability (whether arising in tort, contract or otherwise) whatsoever for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this presentation or its contents or otherwise arising in connection therewith, and makes no representation or warranty, express or implied, for the contents of this presentation including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this presentation or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future.

The statements contained in this document speak only as at the date as of which they are made, and the Company expressly disclaims any obligation or undertaking to supplement, amend or disseminate any updates or revisions to any statements contained herein to reflect any change in events, conditions or circumstances on which any such statements are based. By preparing this presentation, none of the Company, its management, and their respective advisers undertakes any obligation to provide the recipient with access to any additional information or to update this presentation or any additional information or to correct any inaccuracies in any such information which may become apparent. This document does not constitute or form part of and should not be construed as an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company or its subsidiaries or affiliates in any jurisdiction or as an inducement to enter into investment activity. No part of this document, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. You acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company. This document is not financial, legal, tax or other product advice. Any person/ party intending to provide finance/ invest in the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision.

This presentation contains statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers and information currently available with them including with respect to the consolidated results of operations and financial condition, and future events and plans of the Company. These statements can be recognized by the use of words such as “expects”, “plans”, “will”, “estimates”, “intends” or words of similar meaning. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors and assumptions. Neither the Company nor its affiliates or advisors or representatives guarantees that the assumptions underlying such forward-looking statements are free from errors nor do they accept any responsibility for either the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted developments. You are cautioned not to place undue reliance on these forward looking statements, which are based on the current view of the management of the Company on future events. No assurance can be given that future events will occur, or that assumptions are correct. Neither the Company nor its advisors or representatives assume any responsibility to amend, modify or revise any forward-looking statements, on the basis of any subsequent developments, information or events, or otherwise. Certain numbers in these presentations and materials have been subject to routine rounding off and accordingly figures shown as total in tables and diagrams may not be an arithmetic aggregation of the figures that precede them.

This presentation has not been approved and will not or may not be reviewed or approved by any statutory or regulatory authority in India or by any stock exchange in India. This presentation does not purport to be a complete description of the markets conditions or developments referred to in the material. This presentation includes certain industry data and projections that have been obtained from industry publications and surveys. Industry publications and surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance that the information is accurate or complete. Neither the Company nor any of its advisors or representatives have independently verified any of the data from third-party sources or ascertained the underlying economic assumptions relied upon therein. All industry data and projections contained in this presentation are based on data obtained from the sources cited and involve significant elements of subjective judgment and analysis, which may or may not be correct. For the reasons mentioned above, you should not rely in any way on any of the projections contained in this presentation for any purpose.

The distribution of these materials in certain jurisdictions may be restricted by law and persons into whose possession these materials comes should inform themselves about and observe any such restrictions.

This presentation and the information contained herein does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. This presentation is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, and the rules made thereunder, as amended, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India. This presentation is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration.

By accessing this presentation, you accept that this disclaimer and any claims arising out of the use of the information from this presentation shall be governed by the laws of India and only the courts in Chennai, India, and no other courts, shall have jurisdiction over the same.

Content

Financial Performance Snapshot & Business Segment wise Update	4-8
Consolidated Financials	10
Healthcare Services	12-21
Diagnostics & Retail Health (AHLL)	23-25
Digital Health & Pharmacy Distribution (Apollo HealthCo)	27-31
Annexure	33-34

Financial Performance Snapshot Q1FY26

(in ₹ Mio)

		Revenue	Growth YoY(%)	EBITDA(Post Ind AS)	Margin	Growth YoY(%)	PAT		Growth YoY(%)
Healthcare Services		29,351	11%	7,179	24.5%	15%	3,840	13.1%	17%
Apollo HealthCo	Offline PD ^	21,634	18%	1,669	7.7%	20%			
Apollo HealthCo	Online PD^ & 24|7	3,085	26%	(732) Vs (1,163) in Q1F25					
Apollo HealthCo	Total HealthCo	24,718	19%	938	3.8%		569	2.3%	
AHLL		4,351	19%	403	9.3%	31%	(80)		
Consolidated		58,421	15%	8,519	14.6%	26%	4,328	7.4%	42%

^PD:- Pharmacy Distribution

Largest Pan India Hospital Chain



Overseas (Managed)
Bahrain : 1
Bangladesh: 1

	Hospitals	Capacity Census Beds[1]	Operational Census Beds
Overall Total	73	10,187	9,463
Owned Hospitals	45	8,754	8,030
Managed Hospitals	6	790	790
Day Surgery & Cradle (AHLL)	22	643	643

[1]Capacity beds include only census capacity beds and doesn't include emergency, daycare beds, recovery room, dialysis, endoscopy etc.

Healthcare Services Q1 FY26 Snapshot

- 151,558 In-patients ↑ 3%
- ₹ 172,282 Avg Revenue per IP Patient ↑ 9%
- 65% Occupancy

Revenue	₹ 29,351 Mio	↑ 11%
EBITDA	₹ 7,179 Mio	↑ 15%
Margin	24.5%	

AHLL: Retail Health

Apollo Health & Lifestyle Ltd

Out-of-Hospital care

- Outpatient Clinics
- Diagnostics
- Day Surgery centers
- Single Specialty Facilities :- Dialysis, Sugar and Dental

Organizing the unorganized

- Pathology – Organized chains represent only ~30%
- Mother and Child, Specialized Surgical Centers
- IVF Centers

Significant **opportunity to grow** the primary care and diagnostics businesses Plays a vital role in last-mile care delivery, and in ensuring continuum of care for the consumer

AHLL Q1 FY26 Snapshot

- 2,281 Diagnostics Centers
- 288 Clinics
- 154 Dialysis Centers
- 232 Dental Centers

Revenue	₹ 4,351 Mio	↑ 19%
EBITDA	₹ 403 Mio	↑ 31%
Margin	9.3%	

AHL| India's Largest Omni-channel Healthcare Platform

Apollo HealthCo Ltd

Offline Pharmacy Distribution

- **India's largest Organized Pharmacy Platform** with presence in ~1,200+cities/ towns spread across 22 States and 5 union territories.
- **6,742 Operating Stores** as on 30th June 2025.
- **Serving ~ 8.8 lacs customers** 24 x 7 everyday.
- **Private and Generic Label sales at 15.8% (offline) for Q1 FY26.**



Apollo 24|7

Unmatched Size

- **41 Mn.+** Registered Users – **795,275** Daily Active Users
- Serving consumers through **network of 6,742 pharmacies**

Industry-leading Growth at scale

- Platform GMV: INR 682 Cr. in Q1FY26, growth of 23% over Q1 FY25

Full stack digital healthcare platform

- First-in-class AI enabled technologies including India's first Clinical Intelligence Engine

Apollo Telehealth*

- Provides **comprehensive remote healthcare services**.
- Offers **specialized telehealth solutions** like **24/7 Tele-Emergency** and **Tele-Consultancy**.
- Expands access to **healthcare in distant regions**, improving quality of life.
- Operates and maintains Mobile Medical Units/ Mobile Health Units, Patient Facilitation Centres, Digital Dispensaries, and is also engaged in organizing Screening Camps and development of Diagnostic Centres for setting up healthcare awareness programs

*Division of AHEL

- **Virtual Doctor Consultation**
- **Online Booking : Hospitals & Diagnostics**
- **Online Medicine delivery**
- **Health Insurance**
- **Patient e-health records**
- **Condition management**

Health Co Q1 FY26 Snapshot

6,742 Outlets

~14.6% Omni Private label / Generic sales

Revenue	₹ 24,718 Mio	19%
EBITDA	₹ 2,145 Mio (excl 24|7 operating cost & ESOP)	25%
Margin	8.7%	

Clinical Updates and New Initiatives

Hospitals

- Apollo Hospitals,Greams Road : Hybrid TEVAR and EVAR for a 75-year-old with a 10 cm thoracoabdominal aneurysm.
- Apollo Hospitals, Vanagaram: Embolization for Sturge-Weber Syndrome in a 7-year-old.
- Apollo Hospitals, Jayanagar : First mechanical thrombectomy using INARI FlowTriever in Karnataka for massive PE.
- First transcatheter PFO closure in Andhra Pradesh–Telangana using Talisman Occluder
- Apollo Hospitals International Ltd, Ahmedabad won the Excellence in Multi-Specialty Care – West award at the Financial Express – Express Awards.
- Apollo Hospitals, Healthcity, Visakhapatnam received the Excellence in Orthopedic Care – South award at the Financial Express – Express Awards.

AHLL

- Rolled out an Obesity Management Program at Sugar Clinics, featuring specially designed packages centered around Mounjaro (Tirzepatide). Introduced "Apollo on wheels" across a few corporate offices
- New ~45k sq. ft. state-of-the-art Digi-Smart Central Reference Laboratory launched in Chennai. CRL integrates 5 major disciplines into a unified system and has capacity to process ~100,000 samples daily
- Expansion of test-menu to include Couple Karyotyping to detect structural abnormalities, Carrier Screening by CES, Fragile X Syndrome to detect the cause of intellectual disability, HOMA-IR for insulin resistance, TSH Receptor Antibodies, Myositis Profile for inflammatory myopathies, 5G Genotyping for thrombosis, MLPA for SMA, DMD, CAH and HS Troponin for myocardial injury
- Launched new implant system (Straumann) at Apollo Dental

Apollo HealthCo

- Introduction of common cart for pharma and diagnostics business unit – leading to an increase in cross-BU orders
- Expanding the geographical reach by strengthening the customer value proposition of same day delivery in additional 10 cities, resulting in new customer acquisition from the new geographies.
- Continuous improvement in the transacting customers and portfolio consumer base
- Improved sourcing of new users for IP/OP by expanding the health content catalogue and making discovery of doctors easier
- Expanding the insurance offerings by increasing the number of insurers onboarded to 7.

Consolidated Financials

Consolidated Financials Q1FY26

(₹ mio)

₹ Mio		Healthcare Services	Diagnostics & Retail Health	Digital Health & Pharmacy Distribution	Consol
Q1FY26	Total Revenues	29,351	4,351	24,718	58,421
	EBITDA (Pre 24|7 Cost)	7,179	403	2,145	9,727
	margin (%)	24.5%	9.3%	8.7%	16.6%
	24/7 Operating Cost			(963)	(963)
	ESOP(Non Cash expense)			(245)	(245)
	EBITDA	7,179	403	938	8,519
	margin (%)	24.5%	9.3%	3.8%	14.6%
	EBIT	5,610	71	692	6,373
	margin (%)	19.1%	1.6%	2.8%	10.9%
	PBT	5,345	-89	571	5,827
	margin (%)	18.2%	-	2.3%	10.0%
	PAT (Reported)	3,840	-80	569	4,328
Q1FY25	Total Revenues	26,373	3,661	20,821	50,856
	EBITDA (Pre 24|7 Cost)	6,217	309	1,721	8,247
	margin (%)	23.6%	8.4%	8.3%	16.2%
	24/7 Operating Cost			(1,300)	(1,300)
	ESOP(Non Cash expense)			(196)	(196)
	EBITDA	6,217	309	225	6,751
	margin (%)	23.6%	8.4%	1.1%	13.3%
	EBIT	4,878	27	73	4,977
	margin (%)	18.5%	0.7%	0.3%	9.8%
	PBT	4,566	-137	-129	4,300
	margin (%)	17.3%	-	-	8.5%
	PAT (Reported)	3,283	-102	-129	3,052
YOY Growth					
Revenue		11%	19%	19%	15%
EBITDA		15%	31%	317%	26%
PAT		17%	-	-	42%

- Overall **Consolidated Revenue grew by 15% to ₹ 58,421 mio.**
- EBITDA grew by 26% to **₹ 8,519 mio.**
- Consolidated PAT grew by 42% **to ₹ 4,328 mio.**

	HCS	Health Co	AHLL
Gross Debt	21,364	4,308	2,832
Cash & Cash Equivalents*	29,763	901	1,269
Net Debt	-8,399	3,407	1,563

*Includes investments in Liquid funds and FDs of ₹ 27,524 mio.

Consol Gross Debt	28,504
Consol Net Debt	-3,429

Healthcare Services

Hospitals

Healthcare Services Financials

(₹ mio)

₹ Mio	Q1FY26	Q1FY25	YoY
No of Hospitals	45	45	
Operating beds	8,030	7,942	1%
Occupancy	65%	68%	
IP Discharges	151,558	146,862	3%
ALOS	3.14	3.34	-6%
Avg revenue per In Patient (₹)	**172,282**	**158,251**	**9%**
Revenue	**29,351**	**26,373**	**11%**
EBITDA (Post Ind AS 116)	**7,179**	**6,217**	**15%**
margin (%)	**24.5%**	**23.6%**	**88 bps**
EBIT	**5,610**	**4,878**	**15%**
margin (%)	19.1%	18.5%	62 bps
PBT	5,345	4,566	17%
PAT	**3,840**	**3,283**	**17%**
Margin	13.1%	12.4%	63 bps

- Healthcare Services Revenue grew by 11% in Q1FY26 (Inpatient Volume grew by 3% ; Price of and case mix of 8%)
- The reduction in Bangladesh patients has had an impact of 1.5% on HCS Revenue in Q1 FY26.
- Average Revenue per In patient grew by **9% to ₹172,282**

Capital employed (ROCE – Q1FY26)	₹ 78,927	ROCE 28.4%

* capital employed excludes CWIP of ₹ 8,423 mio toward new projects under development

Inpatients Revenue Mix Q1FY26





* Oncology includes Radiotherapy and Chemotherapy

Healthcare Services: Expansion Plan

To add 4,300 capacity beds 3,500 census beds over the next 5 years

Location	Nature	Total Beds	Census Beds	Project Cost (in Crs)
Expected commissioning : FY26				
Royal Mudhol, Pune	Hospital Asset Acquisition	400	325	₹ 630
Sonarpur, Kolkata	Hospital Asset Acquisition	270	220	₹ 310
Gachibowli, Hyderabad	Greenfield - Asset Light	375	300	₹ 515
Gurgaon, NCR	Hospital Asset Acquisition	510	420	₹ 1,190
Defence Colony, Delhi	Brownfield	42	27	₹ 65
Sarjapur-1	Acquisition - Leased facility	200	160	₹ 285
Malleswaram & Mysore Expansion	Brownfield	140	125	₹ 170
		1,937	**1,577**	**₹ 3,165**
Expected commissioning : In next 3 - 4years				
OMR, Chennai	Greenfield	600	500	₹ 945
Varanasi, U.P	Greenfield	400	300	₹ 640
Worli, Mumbai	Greenfield	575	500	₹ 1,315
Lucknow (Expansion), U.P	Brownfield	200	160	₹ 320
Sarjapur-2	Greenfield	500	400	₹ 944
Jubilee Hills (Expansion)	Brownfield	80	70	₹ 220
Secunderabad (Expansion)	Brownfield	80	70	₹ 54
		2,435	**2,000**	**₹ 4,438**
Total		**4,372**	**3,577**	**₹ 7,603**

Continue to evaluate bolt-on acquisitions in select Tier -1 cities & Metros

Total Project Cost of ~₹ 7,600crs with Balance to be spent of ~₹5,400crs.

Current Beds (Total Census) – Q1FY26: **9,463**
Includes Owned, Managed and AHLL

+3,577

Post Expansion: **~13,000**

Healthcare Services : Operational Snapshot



Q1FY26	6 Metros	Non Metros
Operating Beds	4,592	3,438
Occupancy	68%	61%
ARPP -IP^	204,645	124,037
ROCE	29%	25%

^Avg revenue per In Patient

	PAN INDIA		
	Q1FY26	Q1FY25	YoY
Operating Beds	8,030	7,942	1.1%
Bed Occupancy Rate (%)	65%	68%	
Inpatient volume	151,558	146,862	3.2%
Outpatient volume[(1)]	567,128	521,998	8.6%
Inpatient ALOS (days)	3.14	3.34	-6.0%
Total Net Revenue (₹ mio)[(2)]	32,244	28,995	11.2%
Avg revenue per In Patient	172,282	158,251	8.9%

[1] Outpatient Volume represents New Registrations only |[2]Revenue will differ from the consolidated revenues as this includes Delhi which is not consolidated under Ind AS 116 due to joint control

Tamil Nadu Region

Metro:- Chennai ; Non Metro:- Madurai, Karur, Karaikudi, Trichy and Nellore



	Tamil Nadu Region		
	Q1FY26	Q1FY25	YoY
Operating Beds	2,033	2,051	-0.9%
Bed Occupancy Rate (%)	62%	64%	
Inpatient volume	37,522	37,519	0.0%
Outpatient volume[1]	160,700	150,055	7.1%
Inpatient ALOS (days)	3.06	3.18	-3.8%
Total Net Revenue (₹ mio)	9,824	9,016	9.0%
Avg revenue per In Patient	202,525	182,454	11.0%

	Current Beds		Post Expansion
Chennai	1,368	+500	1,868
Total	2,033		2,533

Q1FY26

	Chennai
Operating Beds	1,368
Occupancy	63%
ARPP-IP ^	226,334

	Others
Operating Beds	665
Occupancy	60%
ARPP-IP ^	142,409

Expansion Plan

Location	Nature	Total Beds	Census Beds
OMR, Chennai	Greenfield	600	500

[1] Outpatient Volume represents New Registrations only. ^Avg revenue per In Patient

AP, Telangana Region

Metro:- Hyderabad; Non Metro:- Karimnagar, Vizag and Kakinada

	AP, Telangana Region		
	Q1FY26	Q1FY25	YoY
Operating Beds	1,290	1,240	4.0%
Bed Occupancy Rate (%)	63%	63%	
Inpatient volume	23,271	19,729	18.0%
Outpatient volume[(1)]	75,388	67,687	11.4%
Inpatient ALOS (days)	3.18	3.61	-11.9%
Total Net Revenue (₹ mio)	5,014	4,067	23.3%
Avg revenue per In Patient	182,518	170,228	7.2%

	Current Beds		Post Expansion
Hyderabad	787	+440	1,227
Total	1,290		1,730

Q1FY26

	Hyderabad
Operating Beds	787
Occupancy	68%
ARPP-IP ^	192,637

	Others
Operating Beds	503
Occupancy	56%
ARPP-IP ^	159,494

Expansion Plan

Location	Nature	Total Beds	Census Beds
Gachibowli, Hyderabad	Greenfield - Asset Light	375	300
Jubilee Hills (Expansion)	Brownfield	80	70
Secunderabad (Expansion)	Brownfield	80	70
Total		535	440

[1] Outpatient Volume represents New Registrations only. ^Avg revenue per In Patient

Karnataka Region

Metro:- Bangalore; Non Metro:- Mysore

	Karnataka Region		
	Q1FY26	Q1FY25	YoY
Operating Beds	776	746	4.0%
Bed Occupancy Rate (%)	69%	76%	
Inpatient volume	16,953	17,295	-2.0%
Outpatient volume[1]	70,536	60,211	17.1%
Inpatient ALOS (days)	2.87	2.99	-4.1%
Total Net Revenue (₹ mio)	3,543	3,119	13.6%
Avg revenue per In Patient	176,417	152,804	15.5%

	Current Beds		Post Expansion
Bangalore	563	+685	1,248
Total	776		1,461

Q1FY26

	Bangalore	Others
Operating Beds	563	213
Occupancy	69%	68%
ARPP-IP ^	189,688	134,813

Expansion Plan

Location	Nature	Total Beds	Census Beds
Malleswaram & Mysore Expansion	Brownfield	140	125
Sarjapur-1	Acquisition - Leased facility	200	160
Sarjapur-2	Greenfield	500	400
Total		**840**	**685**

[1] Outpatient Volume represents New Registrations only

^Avg revenue per In Patient

Eastern Region

Metro:- Kolkata; Non Metro:- Guwahati, Bhubaneshwar, Bilaspur and Rourkela

	Eastern Region Q1FY26	Eastern Region Q1FY25	YoY
Operating Beds	1,836	1,827	0.5%
Bed Occupancy Rate (%)	71%	75%	
Inpatient volume	33,317	32,934	1.2%
Outpatient volume[1]	110,302	110,161	0.1%
Inpatient ALOS (days)	3.55	3.81	-6.6%
Total Net Revenue (₹ mio)	6,109	5,709	7.0%
Avg revenue per In Patient	145,192	137,186	5.8%

	Current Beds		Post Expansion
Kolkata	736	+220	956
Total	1,836		2,056

Q1FY26

	Kolkata
Operating Beds	736
Occupancy	76%
ARPP-IP ^	218,451

	Others
Operating Beds	1,100
Occupancy	67%
ARPP-IP ^	99,045

Expansion Plan

Location	Nature	Total Beds	Census Beds
Sonarpur, Kolkata	Hospital Asset Acquisition	270	220

[1] Outpatient Volume represents New Registrations only. ^Avg revenue per In Patient ; Kolkata ARPP-IP Grossed up for fee-for-service doctor fees.

Western Region

Metro:- Mumbai; Non Metro:- Nashik and Ahmedabad

	Western Region		
	Q1FY26	Q1FY25	YoY
Operating Beds	888	861	3.1%
Bed Occupancy Rate (%)	52%	55%	
Inpatient volume	13,133	12,543	4.7%
Outpatient volume[1]	50,839	51,534	-1.3%
Inpatient ALOS (days)	3.22	3.42	-5.9%
Total Net Revenue (₹ mio)	2,464	2,167	13.7%
Avg revenue per In Patient	156,825	139,463	12.4%

	Current Beds		Post Expansion
Mumbai	392	+500	892
Total	888	+825	1,713

Q1FY26

	Mumbai
Operating Beds	392
Occupancy	62%
ARPP-IP ^	185,587

	Others
Operating Beds	496
Occupancy	45%
ARPP-IP ^	125,857

Expansion Plan

Location	Nature	Total Beds	Census Beds
Royal Mudhol, Pune	Hospital Asset Acquisition	400	325
Worli, Mumbai	Greenfield	575	500
Total		**975**	**825**

[1] Outpatient Volume represents New Registrations only. ^Avg revenue per In Patient

Northern Region

Metro:- Delhi; Non Metro:- Lucknow and Indore

	Northern Region		
	Q1FY26	Q1FY25	YoY
Operating Beds	1,207	1,217	-0.8%
Bed Occupancy Rate (%)	70%	72%	
Inpatient volume	27,362	26,842	1.9%
Outpatient volume[1]	99,363	82,350	20.7%
Inpatient ALOS (days)	2.82	2.97	-5.0%
Total Net Revenue (₹ mio)	5,290	4,917	7.6%
Avg revenue per In Patient	163,930	155,288	5.6%

	Current Beds		Post Expansion
Delhi NCR	746	+447	1,193
Total	1,207	+907	2,114

Q1FY26

	Delhi NCR
Operating Beds	746
Occupancy	73%
ARPP-IP ^	189,802

	Others
Operating Beds	461
Occupancy	65%
ARPP-IP ^	124,741

Expansion Plan

Location	Nature	Total Beds	Census Beds
Gurgaon, NCR	Hospital Asset Acquisition	510	420
Varanasi, U.P	Greenfield	400	300
Lucknow (Expansion), U.P	Brownfield	200	160
Defence Colony, Delhi	Brownfield	42	27
Total		**1152**	**907**

[1] Outpatient Volume represents New Registrations only.

^Avg revenue per In Patient

Diagnostics & Retail Health

Apollo Health & Lifestyle Ltd

Executive Summary

Primary Care

Apollo Dialysis Clinics · Apollo Clinic (Expertise. Closer to you.) · Apollo Sugar Clinics · Apollo Dental

- Core revenues of Primary Care grew by ~17% YoY in Q1 FY26, as a result of revamped health check plans and strengthening of corporate outreach
- Preventive Health-checks volume grew by ~46% YoY in Q1 FY26
- Rolled out an integrated obesity management program, expanding the service portfolio
- 1 New Clinic & 8 New Dialysis Centres launched in Q1 FY26

Diagnostics

Apollo DIAGNOSTICS

- New state-of-the-art Digi-Smart Central Reference Laboratory (~45k sq. ft.) launched in Chennai – Combined with existing GRL in Hyderabad, it will result in processing capacity of 1.5 lakh samples/day
- Net addition of 5 Satellite Labs & 65 Collection Centers to the network
- Wellness segment volume grew by ~34% YoY in Q1 FY26 & accounted ~20% of Diagnostics revenue (vs ~18% in FY24)
- Test-menu expansion to cover Couple Karyotyping, Carrier Screening by CES, Fragile X Syndrome, HOMA-IR, TSH Receptor Antibodies, 5G Genotyping etc.

Specialty Care

Apollo Spectra Hospitals (Specialists in Surgery) · Apollo Cradle & Children's Hospital · Apollo Fertility

- Spectra: ~9% YoY revenue growth in Q1 FY26 driven by operationalization of renovated Jaipur center
- Cradle: ~9% YoY revenue growth in Q1 FY26. 1 New Centre to be commissioned in Q3 FY26
- Fertility: ~11% YoY revenue growth in Q1 FY26. Also established a new fertility Knowledge Centre

AHLL Financials Q1FY26

(₹ mio)

		Primary Care	Diagnostics	Specialty Care	Corporate / Intra Group	AHLL
Q1FY26	Revenue	1,135	1,524	1,883	-191	4,351
	EBITDA	197	119	240	-154	403
	margin (%)	17.4%	7.8%	12.8%	-	9.3%
	EBIT	125	52	50	-156	71
	PAT	89	45	-93	-158	-117
Q1FY25	Revenue	964	1,164	1,725	-192	3,661
	EBITDA	180	110	184	-165	309
	margin (%)	18.6%	9.4%	10.7%		8.4%
	EBIT	110	73	12	-168	27
	PAT	79	67	-121	-173	-148
Growth						
Revenue		18%	31%	9%	-	19%
EBITDA		10%	8%	30%	-	31%

- AHLL revenue & EBITDA grew by 19% & 31% YoY in Q1 FY26 respectively; primarily driven by growth in Diagnostics
- Primary care revenue and EBITDA grew by 18% and 10% YoY in Q1 FY26 respectively due to revamped health check plans
- Specialty care EBITDA grew by 30% YoY in Q1 FY26 due to various cost savings measures

	Primary Clinics	Sugar Clinics	Dental Clinics	Dialysis	Diagnostics	Spectra[1]	Birthing Centers[1*]	Total
Network	288	76	232	154	2,281	23	34	3,088
Footfalls / Day	2,521	522	240	2,521	20,820	82	104	26,821
Gross ARPP	2,416	3,236	6,532	1,644	717#	109,144	83,244	1,664#

Includes BOMA[1] | Includes IVF* Without CRL, Diagnostics Gross ARPT is 833# | # Without CRL Gross ARPP is 1978

Diagnostics : Key Parameters

Gross Revenue (INR Mn)



EBITDA (INR Mn)[1]



Operational footprint (as of June 30, 2025)

~330+ Cities presence

108 Labs

2,100+ Collection Centres

3,000+ Pick-up Points (PUPs)

Avg. Footfalls per day & Avg. gross realization per patient (INR)[2,3]



Network Growth – Collection Centers



1. *EBITDA post IND AS 116;*
2. *Footfalls and ARPV for diagnostics represent outpatient / external business*
3. *Without CRL, Diagnostics Gross ARPT is 833*

Digital Health & Pharmacy Distribution

Apollo HealthCo

India's Largest Omni-Channel Healthcare Platform

Apollo 247 Digital Platform

~41 Mn+ Registrations (34Mn ending June-24)

~12,800+ Doctors

Daily Active Users	7.9 Lakh (55% growth over corresponding period)
Daily Consultations	13,000+
Daily Medicine Orders	57,000+ (29% growth over corresponding period)
Daily Sample Collections	~2,500+



- Virtual Doctor Consultation
- Online Booking : Hospitals & Diagnostics
- Online Medicine delivery
- Insurance
- Patient e-health records
- Condition management

Apollo Pharmacy Platform

6,742 Stores	
Added – Q1	119
Closed –Q1	3
Net	116

~14.6%

Omni Private label / generics mix - Q1 FY26



Apollo HealthCo Financials Q1FY26

(₹ mio)

₹ Mio		Offline Pharmacy Distribution	Online Pharmacy Distribution & Apollo 247	Total HealthCo
Q1FY26	**Total Revenues**	**21,634**	**3,085**	**24,718**
	EBITDA (Pre 24|7 Cost)	**1,669**	**476**	**2,145**
	margin (%)	**7.7%**	**15.4%**	**8.7%**
	24/7 Operating Cost		-963	-963
	ESOP(Non Cash expense)		-245	-245
	EBITDA	**1,669**	**-732**	**938**
	margin (%)	**7.7%**	**-**	**3.8%**
	EBIT			692
	PBT			571
	PAT (Reported)			**571**
Q1FY25	**Total Revenues**	**18,369**	**2,452**	**20,821**
	EBITDA (Pre 24|7 Cost)	**1,388**	**334**	**1,721**
	margin (%)	**7.6%**	**13.6%**	**8.3%**
	24/7 Operating Cost		-1,300	-1,300
	ESOP(Non Cash expense)		-196	-196
	EBITDA	**1,388**	**-1,163**	**225**
	margin (%)	**7.6%**	**-**	**1.1%**
	EBIT			73
	PBT			-129
	PAT (Reported)			**-129**
Revenue		18%	26%	19%
EBITDA (Pre 24|7 Cost)		20%	43%	25%

* Excluding 24|7 operating Cost and ESOP Non-Cash Charge

Digital Cash loss* (in Mn)



Healthco Cash profit* (in Mn)



*Cash loss/profit is EBITDA post Ind As excluding ESOP expense

Healthco (Q1' FY26 vs Q1' FY25);

- 19% growth in revenue in Q1' FY26 vs Q1' FY25.
- **PAT positive in Q1'FY26** of Rs. 571 Mn vs **loss** of Rs. 129 Mn in Q1'FY25 on account of growth in operational revenue and optimization of 247 operating cost partially getting offset by increase in non cash charge item (ESOP)

Omnichannel Healthcare Division:

- Omnichannel Pharmacy (AHL+ APL) Business revenue of Rs 31,640 Mn in Q1' FY26 compared to a revenue of Rs. 26,148 Mn in Q1' FY25 (growth of 21%).
- Apollo Telehealth (under AHEL)- While Revenues remain stagnant (Rs.183 Mn in Q1FY26 vs 186 Mn in Q1 FY25), there is positive movement in EBITDA (14.1 Mn in Q1FY26 vs 1.4 Mn in Q1 FY25).

Digital Operational Metrics :

- Platform GMV : Rs 6,825 Mn in Q1' FY26, growth of 23% over Q1' FY25 (5,532 Mn)
- New customer acquisition channel started to gain traction (launch of 19 mins & Omni Acquisition)
- Continuous Improvement in quantitative parameters in Q1' FY26 vs Q1' FY25:
  - 42% YoY growth in Online Pharma Transactions
  - 36% YoY growth in Transacting users.

Offline Segment

- 14% YoY growth in offline transactions (8.0 cr Vs 7.0 cr year back)
- Serving ~8.8 lac offline customers per day

Apollo HealthCo: Composite Scheme as approved by the Board on June 30, 2025

- Proposes to undertake below transactions sequentially, via a scheme of arrangement, subject to requisite corporate and regulatory approvals

Step 1	• Demerger of Omnichannel pharmacy distribution (OCP) and Apollo 24|7 digital platform (shares of AHEL in Apollo Healthco Ltd) & remote telehealth division of AHEL into New Co
Step 2	• Amalgamation of Apollo Healthco Ltd with and into New Co
Step 2	• Amalgamation of Keimed Private Limited with and into New Co

Upon effectiveness of the Scheme (Post Shareholder and NCLT approval),
New Co to become an 'Indian Owned and Controlled Company' (IOCC), and apply for listing on stock exchanges

Composite scheme: Shareholding Structure

Shareholder approved Resultant Group Structure in August 2024



Resultant Group Structure Proposed Now (Post all approvals)

- **Automatic listing of New Co**
- **Direct participation of AHEL shareholders in New Co**



** Includes economic interest of AHEL holding of 49% in FHPL; AHEL effective economic interest through FHPL post merger/ demerger process is ~ 2.5%.

Estimated Listing by Q4FY27 post all approvals.

Combined Proforma Financial Metrics (Proposed New Co) Q1FY26

(₹ mio)

	Combined FY24	Combined FY25	Offline Pharma Distribution	+	Online Pharma Distribution+247	=	Total Healthco	+	Keimed	=	Combined Q1'FY26
Revenue	**137,701**	**163,772**	21,634		3,085		**24,718**		35,606		**44,346**
EBITDA,Pre INDAS	**9,614**	**11,180**	1,612		470		**2,082**		1,096		**3,178**
EBITDA %	**7.0%**	**6.8%**	7.4%		15.2%		**8.4%**		3.1%		**7.2%**
24/7 Operating cost	**-6,186**	**-4,781**	-		-963		**-963**		-		**-963**
ESOP Non Cash charge	**-891**	**-1,076**	-		-245		**-245**		-		**-245**
EBITDA, Pre IndAS	**2,533**	**5,322**	1,612		-737		**874**		1,096		**1,970**
EBITDA %	**1.8%**	**3.2%**	7.4%		N.M		3.5%		3.1%		**4.4%**
Excluding Digital	**6.7%**	**6.4%**									**6.6%**

Company expects to achieve INR 250 bn of run rate annualized revenue in Q4 FY27 with 7% EBITDA

Annexure

Basis of Consolidation

AHEL Standalone Hospitals (100% Ownership)	Location
Chennai Main	Chennai
ACI - Chennai	Chennai
Tondiarpet - Chennai	Chennai
FirstMed - Chennai	Chennai
Apollo Children's Hospital	Chennai
Apollo Specialty, Vanagaram	Chennai
ASH Perungudi	Chennai
Women & Child, Shafee Mohammed Road	Chennai
Apollo Proton & Cancer care	Chennai
Madurai	Madurai
Karur	Karur
Karaikudi	Karaikudi
Trichy	Trichy
Nellore	Nellore
Hyderabad	Hyderabad
Bilaspur	Bilaspur
Rourkela	Odisha
Mysore	Mysore
Vizag (old & new)	Vizag
Karim Nagar	Karim Nagar
Bhubaneswar	Bhubaneswar
Jayanagar	Bangalore
Nashik	Nashik
Malleswaram	Bangalore
Navi Mumbai	Mumbai

Subsidiaries	Location	Description	AHEL Ownership
Material Subs			
Apollo Health Co limited	India	Digital Omni-Channel Healthcare services Platform	99.68%
Apollo Health and Lifestyle Ltd.	India	Clinics, Diagnostics and Daycare	68.84%
Apollo Multispeciality Hospitals Ltd.	Kolkata	Hospital	100.00%
Apollo Medics	Lucknow	Hospital	51.00%
Imperial Hospital and Research Centre Ltd.	Bangalore	Hospital	90.00%
Apollo Hospitals International Ltd.	Ahmedabad	Hospital	50.00%
Assam Hospitals Ltd	Assam	Hospital	70.99%
Apollo Rajshree Hospital	Indore	Hospital	54.63%
Samudra Healthcare Enterprises Ltd.	Kakinada	Hospital	100.00%
Other Subs			
Apollo Hospitals (UK) Ltd	UK	UK Hold Co	100.00%
AB Medical Centres Limited	Chennai	Infrastructure	100.00%
Total Health	India	CSR	100.00%
Apollo Hospitals Singapore.PTE Limited	Singapore	Singapore Hold Co	100.00%
Future Parking Pvt Ltd	Chennai	Infrastructure	100.00%
Apollo Home Health care Ltd	India	Paramedical Services	74.00%
Pinakini Hospitals Ltd.	Nellore	Hospital	80.87%
Sapien Biosciences Pvt Ltd	Hyderabad	Biobanking tissues	70.00%
Apollo Lavasa Health Corporation Ltd	Maharashtra	Hospital	51.00%
Apollo Hospitals North Limited	Gurgaon	Hospital	100.00%
Apollo Hospitals Worli LLP	Mumbai	Hospital	90.10%
Health Axis	Hyderabad	Healthcare Technologies and Remote healthcare	69.99%
Kerala First Health Services Private Limited	Kerala	Hospital	60.00%
Associates	**Location**	**Description**	
Indraprastha Medical Corporation Ltd.	Delhi, Noida	Hospital	22.03%
Family Health Plan Ltd.	India	TPA, Health Insurance	49.00%
ApoKos Rehab Pvt Ltd	Hyderabad	Rehab Centre	50.00%
Stemcyte India Therapautics Pvt Ltd	India	Stemcell Banking	37.75%
Apollo Gleneagles PET-CT Pvt Ltd	Hyderabad	Diagnostics	50.00%

IND AS - 116 : Impact on P&L and Balance Sheet –Q1FY26

AHEL Standalone (post IND AS 116)

Balance sheet

Right of use Asset as of 30th June, 2025 ↑	13,125
Lease liabilities as of 30th June, 2025 ↑	13,035
Equity (Transaction impact as on Apr 01, 2019 - Net of Tax) ↓	2,109

Profit & Loss

Revenue	
Other expenses (Lease rent) ↓	279
EBITDA ↑	279
Amortisation ↑	170
EBIT ↑	108
Finance charge ↑	171
PBT ↓	63

AHEL Consolidated (post IND AS 116)

Balance sheet

Right of use Asset as of 30th June, 2025 ↑	24,578
Lease liabilities as of 30th June, 2025 ↑	26,073
Equity (Transaction impact as on Apr 01, 2019 - Net of Tax) ↓	3,052

Profit & Loss

Revenue	
Other expenses (Lease rent) ↓	664
EBITDA ↑	664
Amortisation ↑	424
EBIT ↑	240
Finance charge ↑	377
PBT ↓	137

Thank you